Literature DB >> 19535995

Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation.

Isabelle Desguerre1, Michelle Mayer, France Leturcq, Jacques-Patrick Barbet, Romain K Gherardi, Christo Christov.   

Abstract

There is considerable interindividual variability in motor function among patients with Duchenne muscular dystrophy (DMD); moreover, pathogenetic mechanisms of motor dysfunction in DMD are not understood. Using multiparametric analysis, we correlated initial histologic alterations in quadriceps muscle biopsies from 25 steroid therapy-free patients with DMD with 13 relevant clinical features assessed by a single clinical team during a long-term period (mean, >10 years). There was no residual muscle dystrophin by immunohistochemistry and Western blot analysis in the biopsies. Myofiber size, hypercontracted fibers, necrotic/basophilic fibers, endomysial and perimysial fibrosis, and fatty degeneration were assessed by morphometry. Endomysial fibrosis was the only myopathologic parameter that significantly correlated with poor motor outcome as assessed by quadriceps muscle strength, manual muscle testing of upper and lower limbs at 10 years, and age at ambulation loss (all p<0.002). Motor outcome and fibrosis did not correlate with genotype. Myofibers exhibited oxidative stress-induced protein alterations and became separated from capillaries by fibrosis that was associated with both increase of CD206+ alternatively activated macrophages and a relative decrease of CD56+ satellite cells (both p<0.0001). This study provides a strong rationale for antifibrotic therapeutic strategies in DMD and supports the view that alternatively activated macrophages that are known to inhibit myogenesis while promoting cellular collagen production play a key role in myofibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19535995     DOI: 10.1097/NEN.0b013e3181aa31c2

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  82 in total

Review 1.  Are human and mouse satellite cells really the same?

Authors:  Luisa Boldrin; Francesco Muntoni; Jennifer E Morgan
Journal:  J Histochem Cytochem       Date:  2010-07-19       Impact factor: 2.479

Review 2.  Fat deposition and accumulation in the damaged and inflamed skeletal muscle: cellular and molecular players.

Authors:  Clara Sciorati; Emilio Clementi; Angelo A Manfredi; Patrizia Rovere-Querini
Journal:  Cell Mol Life Sci       Date:  2015-02-18       Impact factor: 9.261

Review 3.  Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials.

Authors:  Yuko Shimizu-Motohashi; Shouta Miyatake; Hirofumi Komaki; Shin'ichi Takeda; Yoshitsugu Aoki
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

4.  Genome-wide Mechanosensitive MicroRNA (MechanomiR) Screen Uncovers Dysregulation of Their Regulatory Networks in the mdm Mouse Model of Muscular Dystrophy.

Authors:  Junaith S Mohamed; Ameena Hajira; Michael A Lopez; Aladin M Boriek
Journal:  J Biol Chem       Date:  2015-08-13       Impact factor: 5.157

Review 5.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

6.  Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.

Authors:  Ingrid E C Verhaart; Hans Heemskerk; Tatyana G Karnaoukh; Ingrid G M Kolfschoten; Anne Vroon; Gert-Jan B van Ommen; Judith C T van Deutekom; Annemieke Aartsma-Rus
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

7.  Age-related T2 changes in hindlimb muscles of mdx mice.

Authors:  Ravneet S Vohra; Sunita Mathur; Nathan D Bryant; Sean C Forbes; Krista Vandenborne; Glenn A Walter
Journal:  Muscle Nerve       Date:  2015-07-14       Impact factor: 3.217

8.  Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.

Authors:  Nicholas P Whitehead; Kenneth L Bible; Min Jeong Kim; Guy L Odom; Marvin E Adams; Stanley C Froehner
Journal:  J Physiol       Date:  2016-10-13       Impact factor: 5.182

Review 9.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

10.  Skeletal muscle fibrosis is associated with decreased muscle inflammation and weakness in patients with chronic kidney disease.

Authors:  Matthew K Abramowitz; William Paredes; Kehao Zhang; Camille R Brightwell; Julia N Newsom; Hyok-Joon Kwon; Matthew Custodio; Rupinder S Buttar; Hina Farooq; Bushra Zaidi; Rima Pai; Jeffrey E Pessin; Meredith Hawkins; Christopher S Fry
Journal:  Am J Physiol Renal Physiol       Date:  2018-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.